According to the company, geneX is a synthetic bone graft material with a unique bi-phasic composition manufactured through a proprietary process that confers the product with a reproducible negative surface charge. This property stimulates bone cell activity, accelerating bone formation and fusion by harnessing key proteins and directing osteoblast adhesion and proliferation for rapid osteogenesis. geneX is fully resorbable and is completely replaced by bone.
Stephen Bratt, managing director of Biocomposites, said: geneX is the only synthetic biomaterial to show spine fusion equivalent to autograft when used as a stand-alone graft material in the clinically relevant ‘Boden’ rabbit model. This response has previously only been demonstrated using best management practices. The encouraging clinical results are supportive of the scientific evidence thus far generated, for the unique affinity that geneX shows for bone forming cells.
Biocomposites is a privately held leading developer, manufacturer and distributor of synthetic, tissue regeneration products. The company has a broad range of products that addresses the clinical and economic needs of medical specialties in orthopaedics and dentistry.